Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Proportion of patients without transfusion after first month.
Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety
18 Years to 80 Years (Adult, Older Adult)
December 26, 2005
May 18, 2011
† Study has passed its completion date and status has not been verified in more than two years.